|Reference : Management of inflammatory bowel disease in pregnancy|
|Scientific journals : Article|
|Human health sciences : Gastroenterology & hepatology|
Human health sciences : Immunology & infectious disease
|Management of inflammatory bowel disease in pregnancy|
|Vermeire, Séverine [Katholieke Universiteit Leuven - KUL > UZ Gasthuisberg > Gastroenterology > >]|
|Carbonnel, Franck [CHU Jean Minjoz - Besançon > > Gastroentérologie et nutrition > >]|
|Coulie, Pierre [Université Catholique de Louvain - UCL > de Duve Institute > Physiology and Immunology > >]|
|Geenen, Vincent [Université de Liège - ULg > > Centre d'immunologie >]|
|Hazes, Johanna M.W. [ > > ]|
|Masson, Pierre [Université Catholique de Louvain - UCL > de Duve Institut > > >]|
|de Keyser, Filip [Ghent University > Rheumatology > > >]|
|Louis, Edouard [Université de Liège - CHU > Gastroentérologie > > >]|
|Journal of Crohn’s and Colitis [=JCC]|
|[en] Inflammatory bowel disease ; Crohn's disease ; Ulcerative colitis ; Pregnancy ; Fertility ; Drug treatment|
|[en] Background. Inflammatory bowel disease (IBD) is a chronic disease affecting mainly young
people in their reproductive years. IBD therefore has a major impact on patients’ family
planning decisions. Management of IBD in pregnancy requires a challenging balance between
optimal disease control and drug safety considerations.
Aim. Provide a framework for clinical decision making in IBD based on review of the
literature on pregnancy-related topics.
Methods. Medline searches with search terms ‘IBD’, ‘Crohn’s disease’ or ‘ulcerative colitis’
in combination with keywords for the topics fertility, pregnancy, congenital abnormalities and
drugs names of drugs used for treatment of IBD.
Results. IBD patients have normal fertility, except for women after ileal pouch-anal
anastomosis (IPAA) and men under sulfasalazine treatment. Achieving and maintaining
disease remission is a key factor for successful pregnancy outcomes in this population, as
active disease at conception carries an increased risk of preterm delivery and low birth weight.
Clinicians should discuss the need for drug therapy to maintain remission with their patients
in order to ensure therapy compliance. Most IBD drugs are compatible with pregnancy,
except for methotrexate and thalidomide. If possible, anti-TNF therapy should be stopped by
the end of the second trimester and the choice of delivery route should be discussed with the
Conclusions. Disease control prior to conception and throughout pregnancy are the
cornerstones of successful pregnancy management in IBD patients.
|Researchers ; Professionals ; Students|
|File(s) associated to this reference|
All documents in ORBi are protected by a user license.